TransMedics (TMDX) Net Income towards Common Stockholders (2018 - 2026)

TransMedics' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at $7.3 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 73.9% year-over-year to $7.3 million; the TTM figure through Mar 2026 stood at $85.1 million (up 65.23% YoY), while the FY2025 annual figure was $83.9 million, up 135.26% from the prior year.
• Net Income towards Common Stockholders was $7.3 million for Q1 2026 at TransMedics, down from $18.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $34.9 million in Q2 2025 to a low of -$25.4 million in Q3 2023.
• Historically, Net Income towards Common Stockholders has averaged $6.6 million across 5 years, with a median of $7.1 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders tumbled 242.34% in 2023, then jumped 1318.18% in 2024.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$6.7 million in 2022, then soared by 537.51% to $29.4 million in 2023, then plunged by 75.94% to $7.1 million in 2024, then soared by 162.7% to $18.6 million in 2025, then plunged by 60.63% to $7.3 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $7.3 million (Q1 2026), $18.6 million (Q4 2025), and $24.3 million (Q3 2025), per Business Quant data.